用阿维巴坦联合制剂检测已鉴定的产β-内酰胺酶菌株的体外敏感性。
In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations.
作者信息
Li Henry, Estabrook Mark, Jacoby George A, Nichols Wright W, Testa Raymond T, Bush Karen
机构信息
Indiana University, Bloomington, Indiana, USA.
Lahey Hospital and Medical Center, Burlington, Massachusetts, USA.
出版信息
Antimicrob Agents Chemother. 2015 Mar;59(3):1789-93. doi: 10.1128/AAC.04191-14. Epub 2014 Dec 22.
Abstract
Avibactam, a broad-spectrum β-lactamase inhibitor, was tested with ceftazidime, ceftaroline, or aztreonam against 57 well-characterized Gram-negative strains producing β-lactamases from all molecular classes. Most strains were nonsusceptible to the β-lactams alone. Against AmpC-, extended-spectrum β-lactamase (ESBL)-, and KPC-producing Enterobacteriaceae or Pseudomonas aeruginosa, avibactam lowered ceftazidime, ceftaroline, or aztreonam MICs up to 2,048-fold, to ≤4 μg/ml. Aztreonam-avibactam MICs against a VIM-1 metallo-β-lactamase-producing Enterobacter cloacae and a VIM-1/KPC-3-producing Escherichia coli isolate were 0.12 and 8 μg/ml, respectively.
摘要
阿维巴坦是一种广谱β-内酰胺酶抑制剂，它与头孢他啶、头孢洛林或氨曲南联合，对57株特征明确的、产生所有分子类型β-内酰胺酶的革兰氏阴性菌进行了测试。大多数菌株单独对β-内酰胺类药物不敏感。对于产AmpC酶、超广谱β-内酰胺酶（ESBL）和KPC酶的肠杆菌科细菌或铜绿假单胞菌，阿维巴坦可将头孢他啶、头孢洛林或氨曲南的最低抑菌浓度（MIC）降低至≤4μg/ml，降幅高达2048倍。氨曲南-阿维巴坦对一株产VIM-1金属β-内酰胺酶的阴沟肠杆菌和一株产VIM-1/KPC-3的大肠杆菌分离株的MIC分别为0.12μg/ml和8μg/ml。
相似文献
1
In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations.用阿维巴坦联合制剂检测已鉴定的产β-内酰胺酶菌株的体外敏感性。
Antimicrob Agents Chemother. 2015 Mar;59(3):1789-93. doi: 10.1128/AAC.04191-14. Epub 2014 Dec 22.
2
In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.日本分离的产β-内酰胺酶革兰阴性细菌对头孢他啶、头孢洛林和氨曲南-阿维巴坦联合用药的体外药敏研究
J Infect Chemother. 2015 Feb;21(2):148-51. doi: 10.1016/j.jiac.2014.08.028. Epub 2014 Oct 25.
3
In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates.头孢他啶、头孢洛林和氨曲南单独及与阿维巴坦联合对欧洲革兰氏阴性和革兰氏阳性临床分离株的体外活性。
Int J Antimicrob Agents. 2015 Jun;45(6):641-6. doi: 10.1016/j.ijantimicag.2014.12.033. Epub 2015 Feb 17.
4
Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.头孢他啶、头孢洛林和氨曲南单独及与阿维巴坦联合使用对表达选定单一β-内酰胺酶的同基因大肠杆菌菌株的活性。
Diagn Microbiol Infect Dis. 2015 May;82(1):65-9. doi: 10.1016/j.diagmicrobio.2015.02.003. Epub 2015 Feb 14.
5
The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.头孢他啶、头孢洛林和氨曲南与阿维巴坦联合应用对目标革兰氏阴性菌的抗生素后效应及β-内酰胺酶抑制剂后效应
Lett Appl Microbiol. 2016 Aug;63(2):96-102. doi: 10.1111/lam.12592.
6
In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.NXL104（阿维巴坦）联合β-内酰胺类药物对包括产 OXA-48 碳青霉烯酶肺炎克雷伯菌在内的革兰氏阴性菌的体外活性。
Int J Antimicrob Agents. 2012 Jan;39(1):86-9. doi: 10.1016/j.ijantimicag.2011.09.012. Epub 2011 Oct 29.
7
The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.在感染体外模型中研究了阿维巴坦与头孢洛林或头孢他啶联合使用对产β-内酰胺酶肠杆菌科细菌的药效学。
J Antimicrob Chemother. 2017 Mar 1;72(3):762-769. doi: 10.1093/jac/dkw480.
8
Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).头孢地尔罗与新型β-内酰胺类-β-内酰胺酶抑制剂联合制剂对产金属β-内酰胺酶革兰氏阴性杆菌的活性：一项为期两年（2019-2020 年）研究的见解。
J Chemother. 2023 May;35(3):198-204. doi: 10.1080/1120009X.2022.2090615. Epub 2022 Jun 22.
9
Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types.头孢洛林-阿维巴坦对革兰氏阴性菌群体的活性测试，包括表达一种或多种β-内酰胺酶和携带各种葡萄球菌盒式染色体 mec 类型的耐甲氧西林金黄色葡萄球菌的菌株。
Antimicrob Agents Chemother. 2012 Sep;56(9):4779-85. doi: 10.1128/AAC.00817-12. Epub 2012 Jun 25.
10
Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.氨曲南联合克拉维酸、他唑巴坦或阿维巴坦治疗产金属β-内酰胺酶革兰氏阴性菌感染。
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.00010-19. Print 2019 May.
引用本文的文献
1
Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients.群体药代动力学/药效学建模以优化成人患者的氨曲南-阿维巴坦给药方案。
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0195024. doi: 10.1128/aac.01950-24. Epub 2025 Jun 18.
2
[In vitro activity of ceftazidime- avibactam and ceftolozane- tazobactam against clinical isolates of enterobacteriaceae and : results from a trauma center and burn unit in tunisia].[头孢他啶-阿维巴坦和头孢洛扎-他唑巴坦对突尼斯一家创伤中心和烧伤科肠杆菌科临床分离株的体外活性：结果]
Ann Burns Fire Disasters. 2025 Mar 31;38(1):31-37. eCollection 2025 Mar.
3
Carbapenem-resistant infections in Chinese children: activities of ceftazidime-avibactam and aztreonam-avibactam against carbapenemase-producing strains in a two-center study.中国儿童碳青霉烯类耐药感染：头孢他啶-阿维巴坦和氨曲南-阿维巴坦对产碳青霉烯酶菌株活性的双中心研究
Front Cell Infect Microbiol. 2025 Mar 26;15:1545999. doi: 10.3389/fcimb.2025.1545999. eCollection 2025.
4
The in vitro synergistic and antibiofilm activity of Ceftazidime/avibactam against Achromobacter species recovered from respiratory samples of cystic fibrosis patients.头孢他啶/阿维巴坦对从囊性纤维化患者呼吸道样本中分离出的无色杆菌属细菌的体外协同及抗生物膜活性。
Eur J Clin Microbiol Infect Dis. 2025 Mar;44(3):587-596. doi: 10.1007/s10096-024-05017-0. Epub 2024 Dec 20.
5
Prevention and potential remedies for antibiotic resistance: current research and future prospects.抗生素耐药性的预防与潜在补救措施：当前研究与未来展望
Front Microbiol. 2024 Oct 3;15:1455759. doi: 10.3389/fmicb.2024.1455759. eCollection 2024.
6
Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation.氨曲南-阿维巴坦的剂量选择，包括针对肾功能损害的调整，用于IIa期和III期评估。
Eur J Clin Pharmacol. 2024 Apr;80(4):529-543. doi: 10.1007/s00228-023-03609-x. Epub 2024 Jan 22.
7
Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical Laboratory.临床实验室中新型β-内酰胺类及β-内酰胺类联合制剂的检测方法
Antibiotics (Basel). 2023 Dec 5;12(12):1700. doi: 10.3390/antibiotics12121700.
8
Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Enterobacterales Analyzed by ICU and Non-ICU Wards, Infection Sources, and Geographic Regions: ATLAS Program 2016-2020.通过重症监护病房和非重症监护病房、感染源及地理区域分析氨曲南-阿维巴坦及对照药物对肠杆菌科细菌的抗菌活性：2016 - 2020年ATLAS项目
Antibiotics (Basel). 2023 Nov 3;12(11):1591. doi: 10.3390/antibiotics12111591.
9
In vitro Activity of Cefepime/Avibactam Against Carbapenem Resistant and Integrative Metabolomics-Proteomics Approach for Resistance Mechanism: A Single-Center Study.头孢吡肟/阿维巴坦对碳青霉烯耐药菌的体外活性及耐药机制的整合代谢组学-蛋白质组学方法：一项单中心研究
Infect Drug Resist. 2023 Sep 11;16:6061-6077. doi: 10.2147/IDR.S420898. eCollection 2023.
10
Penicillin-Binding Protein 5/6 Acting as a Decoy Target in Pseudomonas aeruginosa Identified by Whole-Cell Receptor Binding and Quantitative Systems Pharmacology.青霉素结合蛋白 5/6 作为铜绿假单胞菌的诱饵靶点通过全细胞受体结合和定量系统药理学鉴定。
Antimicrob Agents Chemother. 2023 Jun 15;67(6):e0160322. doi: 10.1128/aac.01603-22. Epub 2023 May 18.
本文引用的文献
1
Carbapenemases: Partners in crime.碳青霉烯酶：罪魁祸首
J Glob Antimicrob Resist. 2013 Mar;1(1):7-16. doi: 10.1016/j.jgar.2013.01.005. Epub 2013 Mar 1.
2
Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups.美国九个普查地区肠杆菌科中β-内酰胺酶的当代多样性，以及针对产生最常见β-内酰胺酶群的分离株测试头孢他啶-阿维巴坦的活性。
Antimicrob Agents Chemother. 2014;58(2):833-8. doi: 10.1128/AAC.01896-13. Epub 2013 Nov 18.
3
In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.2010 年至 2012 年加拿大医院分离的革兰阴性和革兰阳性病原菌的体外研究：来自 CANWARD 监测研究的结果。
Antimicrob Agents Chemother. 2013 Nov;57(11):5600-11. doi: 10.1128/AAC.01485-13. Epub 2013 Aug 26.
4
Kinetics of avibactam inhibition against Class A, C, and D β-lactamases.阿维巴坦抑制 A、C 和 D 类β-内酰胺酶的动力学。
J Biol Chem. 2013 Sep 27;288(39):27960-71. doi: 10.1074/jbc.M113.485979. Epub 2013 Aug 2.
5
Antimicrobial activity of ceftaroline-avibactam tested against clinical isolates collected from U.S. Medical Centers in 2010-2011.2010-2011 年美国医疗中心临床分离株检测头孢洛林-他唑巴坦的抗菌活性。
Antimicrob Agents Chemother. 2013 Apr;57(4):1982-8. doi: 10.1128/AAC.02436-12. Epub 2013 Feb 4.
6
Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.头孢他啶-阿维巴坦：一种新型头孢菌素/β-内酰胺酶抑制剂复方制剂。
Drugs. 2013 Feb;73(2):159-77. doi: 10.1007/s40265-013-0013-7.
7
In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.NXL104（阿维巴坦）联合β-内酰胺类药物对包括产 OXA-48 碳青霉烯酶肺炎克雷伯菌在内的革兰氏阴性菌的体外活性。
Int J Antimicrob Agents. 2012 Jan;39(1):86-9. doi: 10.1016/j.ijantimicag.2011.09.012. Epub 2011 Oct 29.
8
Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae.NXL104 联合头孢他啶和氨曲南对产碳青霉烯酶肠杆菌科的活性。
Antimicrob Agents Chemother. 2011 Jan;55(1):390-4. doi: 10.1128/AAC.00756-10. Epub 2010 Nov 1.
9
Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance.不同碳青霉烯类药物和给药方案对三种具有不同耐药机制的同源铜绿假单胞菌耐药性产生的影响。
Antimicrob Agents Chemother. 2010 Jun;54(6):2638-45. doi: 10.1128/AAC.01721-09. Epub 2010 Mar 22.
10
Interactions of ceftobiprole with beta-lactamases from molecular classes A to D.头孢托罗与A至D类分子的β-内酰胺酶的相互作用。
Antimicrob Agents Chemother. 2007 Sep;51(9):3089-95. doi: 10.1128/AAC.00218-07. Epub 2007 Jun 25.
Zotero 插件